Takeda 0 for 4 against nausea and vomiting after axing another asset

Takeda has ended development of its nausea and vomiting drug candidate for strategic reasons, continuing its multi-year struggles in the therapeutic area. Takeda has ended development of its nausea and vomiting drug candidate for strategic reasons, continuing its multi-year struggles in the therapeutic area. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special Report Awards Gala Awards Outsourcing Awards Innovation Awards Resources Fierce Events Industry Events Webinars Podcasts…

Source: FierceBiotech